

## ■ General Information

### Applications

- Immunohistochemistry
  - TUNEL for apoptosis
- In situ hybridization (ISH)
  - mRNA
  - miRNA
  - Fluorescent In situ hybridization (FISH)

### Storage and stability

- Individual slide is put in an air-tight pack with inert gas.
- If the slides are stored at 4C, they are good for up to one year.

### How processed

- Tissues were initially fixed with formalin except for some of the animal tissues
- Then, dehydrated with gradient ethanol; typically 1 hour each progressive steps; 70%, 90%, 95%, 99%, 100% x 3 times.
- Cleared by xylene, three changes for 1 hour each.
- Infiltrated with 60°C paraffin, three changes for 1 hour each
- Sectioned by microtome in 4 µm thickness

### Before use

- Dry slides for 1 hour in a oven at 60C.
- Dewax slides in xylene for 4 minutes x 5 times.
- Hydrate slides in 100%, 95% and 75% ethanol for 3 minutes x 2 times each.
- Immerse slides in tap water for 5 minutes.

### Slide orientation

- In most of the slides with 59 or 60 cores, the orientation is as below unless indicated otherwise. #60 location is usually filled with carbon for orientation.

Shaded area	1	2	3	4	5	6	7	8	9	10
	11	12	13	14	15	16	17	18	19	20
	21	22	23	24	25	26	27	28	29	30
	30	32	33	34	35	36	37	38	39	40
	41	42	43	44	45	46	47	48	49	50
	51	52	53	54	55	56	57	58	59	60

## ■ Tissue types\*

The "tissue type" column in the data sheet denotes the following categories.

1. normal tissue from a non-cancer patient
2. normal tissue from a cancer patient, but the cancer involves unrelated organ
3. normal tissue adjacent to the cancer
4. benign tumor
5. tumor of borderline malignancy or uncertain malignant potential
6. cancer

## NBP2-30276 - Human Liver Tissue MicroArray (Non-Neoplastic)

No.	Age	Sex	Organ	Diagnosis	Associated lesion	No. of NBP2-30271#	Tissue type*
101	60	F	Liver	macronodular cirrhosis	hepatocellular carcinoma	1	3
102	59	M	Liver	macronodular cirrhosis	hepatocellular carcinoma	2	3
103	45	M	Liver	reactive hepatitis	hepatocellular carcinoma	3	3
104	60	M	Liver	reactive hepatitis	rectum adenocarcinoma	.	2
105	47	M	Liver	nonspecific reactive change	rectum adenocarcinoma	.	2
106	50	M	Liver	reactive hepatitis	stomach adenocarcinoma	.	2
107	66	M	Liver	reactive hepatitis	hepatocellular carcinoma	7	3
108	52	M	Liver	nonspecific reactive hepatitis	cholangiocarcinoma	.	3
109	48	M	Liver	reactive hepatitis with steatosis	gallbladder adenocarcinoma	.	2
110	71	M	Liver	macronodular cirrhosis	hepatocellular carcinoma	.	3
111	52	F	Liver	reactive hepatitis	gallbladder adenocarcinoma	.	2
112	59	M	Liver	nonspecific change	colon adenocarcinoma	12	2
113	58	M	Liver	reactive hepatitis with cholestasis	bile duct carcinoma	.	3
114	30	M	Liver	reactive hepatitis with cholestasis	bile duct adenocarcinoma	.	3
115	45	M	Liver	chronic active hepatitis	colon adenocarcinoma	.	2
116	62	M	Liver	nonspecific reactive change	colon adenocarcinoma	.	2
117	68	M	Liver	reactive hepatitis	cholangiocarcinoma	17	3
118	52	M	Liver	nonspecific reactive change with steatosis	rectum adenocarcinoma	.	2
119	45	M	Liver	chronic active hepatitis	hepatocellular carcinoma	19	3
120	52	M	Liver	nonspecific reactive change	colon adenocarcinoma	20	2
121	47	M	Liver	nonspecific reactive change	rectum adenocarcinoma	21	2
122	39	F	Liver	macronodular cirrhosis	hepatocellular carcinoma	22	3
123	37	M	Liver	chronic persistent hepatitis	hepatocellular carcinoma	.	3
124	60	M	Liver	macro- and micronodular cirrhosis	hepatocellular carcinoma	24	3
125	56	M	Liver	reactive hepatitis with steatosis	hepatocellular carcinoma	25	3
126	55	M	Liver	macronodular cirrhosis	hepatocellular carcinoma	26	3
127	62	M	Liver	reactive hepatitis	hepatocellular carcinoma	27	3
128	52	M	Liver	chronic persistent hepatitis	hepatocellular carcinoma	28	3
129	64	M	Liver	macronodular cirrhosis	hepatocellular carcinoma	29	3
130	66	M	Liver	reactive hepatitis	hepatocellular carcinoma	30	3
131	54	F	Liver	macronodular cirrhosis	hepatocellular carcinoma	31	3
132	56	M	Liver	chronic active hepatitis	hepatocellular carcinoma	32	3
133	57	M	Liver	macronodular cirrhosis	hepatocellular carcinoma	33	3
134	61	M	Liver	macronodular cirrhosis	hepatocellular carcinoma	34	3
135	75	M	Liver	micronodular cirrhosis	hepatocellular carcinoma	.	3
136	53	M	Liver	chronic active hepatitis with steatosis	hepatocellular carcinoma	36	3
137	52	M	Liver	macro- and micronodular cirrhosis	hepatocellular carcinoma	.	3
138	65	M	Liver	chronic active hepatitis	hepatocellular carcinoma	38	3
139	58	F	Liver	macro- and micronodular cirrhosis	hepatocellular carcinoma	.	3
140	61	M	Liver	macronodular cirrhosis	hepatocellular carcinoma	40	3
141	52	M	Liver	micronodular cirrhosis	hepatocellular carcinoma	.	3
142	57	M	Liver	macronodular cirrhosis	hepatocellular carcinoma	42	3
143	63	M	Liver	chronic active hepatitis	hepatocellular carcinoma	43	3
144	54	M	Liver	chronic active hepatitis	hepatocellular carcinoma	44	3
145	44	M	Liver	macronodular cirrhosis	hepatocellular carcinoma	45	3
146	40	M	Liver	macro- and micronodular cirrhosis	hepatocellular carcinoma	.	3
147	63	F	Liver	macro- and micronodular cirrhosis	hepatocellular carcinoma	.	3
148	64	M	Liver	chronic active hepatitis	hepatocellular carcinoma	48	3
149	60	F	Liver	macronodular cirrhosis	hepatocellular carcinoma	.	3
150	45	M	Liver	chronic active hepatitis	cholangiocarcinoma	50	3
151	58	F	Liver	reactive hepatitis	cholangiocarcinoma	51	3
152	64	M	Liver	reactive hepatitis	cholangiocarcinoma	52	3
153	62	M	Liver	macronodular cirrhosis	hepatocellular carcinoma	.	3
154	65	F	Liver	macronodular cirrhosis	hepatocellular carcinoma	.	3
155	57	F	Liver	chronic active hepatitis	hepatocellular carcinoma	55	3
156	64	M	Liver	macronodular cirrhosis	hepatocellular carcinoma	.	3
157	47	M	Liver	chronic active hepatitis	hepatocellular carcinoma	.	3
158	43	M	Liver	micronodular cirrhosis	hepatocellular carcinoma	.	3
159	42	F	Liver	reactive hepatitis	hepatocellular carcinoma	59	3
160	.	.	Carbon	.	.	.	.

#: Cancer tissue in NBP2-30271 of corresponding number is from the identical patient.